AbbVie Inc. $ABBV Shares Sold by Benjamin Edwards Inc.

Key Points

• Benjamin Edwards Inc. reduced its AbbVie stake by 3.4% in the second quarter, selling 11,582 shares and retaining 327,322 shares valued at approximately $82.4 million. Institutional investors and hedge funds collectively own 70.23% of AbbVie.
• AbbVie reported quarterly earnings of $3.65 per share, exceeding estimates of $3.61, while revenue rose 10.2% year over year to $16.99 billion. The company guided for third-quarter 2026 EPS of $3.84–$3.88.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $275.95, compared with the stock’s opening price of $256.27. AbbVie also pays a quarterly dividend of $1.73 per share, equivalent to a 2.7% annualized yield.

Benjamin Edwards Inc. reduced its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 3.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 327,322 shares of the company's stock after selling 11,582 shares during the period. AbbVie comprises 0.8% of Benjamin Edwards Inc.'s investment portfolio, making the stock its 20th largest holding. Benjamin Edwards Inc.'s holdings in AbbVie were worth $82,385,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Ranch Capital Advisors Inc. increased its stake in AbbVie by 37.0% in the first quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company's stock valued at $3,238,000 after purchasing an additional 4,017 shares during the last quarter. Capital Advisors Inc. OK lifted its position in shares of AbbVie by 11.2% during the 2nd quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company's stock worth $112,516,000 after buying an additional 45,132 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab acquired a new position in shares of AbbVie in the 2nd quarter valued at $23,557,000. Wedge Capital Management L L P NC grew its position in shares of AbbVie by 7.5% in the 2nd quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company's stock valued at $33,865,000 after buying an additional 9,380 shares during the last quarter. Finally, Mission Wealth Management LP grew its position in shares of AbbVie by 119.1% in the 2nd quarter. Mission Wealth Management LP now owns 69,052 shares of the company's stock valued at $17,376,000 after buying an additional 37,531 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Stock Down 0.1%

NYSE ABBV opened at $256.27 on Tuesday. The stock has a market capitalization of $452.78 billion, a P/E ratio of 72.39, a P/E/G ratio of 1.16 and a beta of 0.29. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47. The firm has a 50-day moving average price of $254.71 and a 200 day moving average price of $230.21.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the prior year, the company posted $2.97 earnings per share. AbbVie's quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts expect that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were given a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. AbbVie's payout ratio is presently 195.48%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. HSBC reissued a "buy" rating and issued a $300.00 price target on shares of AbbVie in a research report on Monday, July 6th. Royal Bank Of Canada lifted their target price on AbbVie from $260.00 to $280.00 and gave the stock an "outperform" rating in a research report on Friday, July 10th. Guggenheim upped their target price on AbbVie from $261.00 to $288.00 and gave the company a "buy" rating in a research report on Tuesday, August 4th. Evercore set a $235.00 price target on AbbVie in a research note on Friday, May 15th. Finally, JPMorgan Chase & Co. boosted their price objective on AbbVie from $260.00 to $280.00 and gave the company an "overweight" rating in a research note on Thursday, July 9th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $275.95.

Insider Transactions at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company's stock, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.06% of the company's stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.